These data highlight that the AIM2/IL-1α/TGF-β axis is not altered by the administration of Dexamethasone, implying that this biological pathway is not monitored from the actual therapeutic options used for COPD patients. The gene discussed is AIM2; the disease is chronic obstructive pulmonary disease.